שווי פעילות לרווח לפני ריבית, מסים ופחת AnaptysBio (ANAB)

AnaptysBio, Inc. (ANAB) utilizes an asset-light model by outsourcing antibody production to third-party contractors. The EV/EBITDA multiple reflects the dynamics of this approach, where the 11.23 level captures the current state. Revenues are based on royalties from the GSK partnership, while valuation growth relies on the anticipation of Phase 2b data for dermatology drugs.

The EV/EBITDA multiple relates the total enterprise value, including net debt, to operating profit, allowing an investor to assess the market revaluation of assets relative to their ability to generate cash flow. An EV/EBITDA valuation analysis for AnaptysBio, Inc. (ANAB) is critical, as in the absence of commercial sales, the company's value is sustained by licensing payments and expectations of FDA regulatory approval for its drugs.